This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Biomerica secures $1.75M IVD contract
Business contract agreement

Biomerica secures $1.75M IVD contract

Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This agreement is expected to positively impact Biomerica's stock price due to the new revenue stream and validation of its CDMO capabilities. The market will likely view this as a strategic move to monetize existing assets and diversify revenue.

Biotechnology Medical Devices
Event Summary

Biomerica, Inc. announced it has entered into a Master Services Agreement (MSA) with a confidential life sciences company to develop proprietary in vitro diagnostic (IVD) assays. The agreement has an initial contract development target fee of over $1.75 million, to be earned across multiple Statements of Work (SOWs) over an initial three-year term with automatic one-year renewals. This CDMO engagement leverages Biomerica's existing ELISA-based assay development expertise and infrastructure, providing a capital-efficient, parallel revenue stream alongside its core inFoods IBS program. The development work will be performed at Biomerica's FDA-licensed facility in Irvine, California, with revenue recognized on a milestone-completion basis.

Entities Involved
priv
Biomerica
Biomerica entered into a Master Services Agreement with a confidential life sciences company, securing a contract development fee of over $1.75 million for IVD diagnostic development. This agreement is expected to generate a new revenue stream for Biomerica, leveraging its existing infrastructure and expertise.
Importance 100.0 Sentiment 50.0
per
Zack Irani
Zack Irani, CEO of Biomerica, provided commentary on the significance of the MSA, highlighting its role in generating direct revenue from the company's scientific infrastructure while maintaining focus on inFoods IBS.
Importance 70.0 Sentiment 40.0
govactor
United States — Food and Drug Administration
Biomerica's facility is FDA-licensed, which is a prerequisite for the development work under the MSA, indicating compliance with regulatory standards.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.